QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
LON:OXB

Oxford Biomedica (OXB) Share Forecast, Price & News

GBX 469
+6.50 (+1.41%)
(As of 06/6/2023 ET)
Compare
Today's Range
458.50
469
50-Day Range
401
469
52-Week Range
276.62
575
Volume
39,861 shs
Average Volume
102,604 shs
Market Capitalization
£454.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 1,010

OXB stock logo

About Oxford Biomedica (LON:OXB) Stock

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock News Headlines

Oxford Biomedica (LON:OXB) Price Target Cut to GBX 1,010
The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
Oxford Biomedica Posts FY Loss
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
CGT CDMO Market Share and Forecast till 2030
See More Headlines

OXB Price History

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
744
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,010
High Stock Price Forecast
GBX 1,010
Low Stock Price Forecast
GBX 1,010
Forecasted Upside/Downside
+115.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-39,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£139.99 million
Cash Flow
GBX 156 per share
Book Value
GBX 213 per share

Miscellaneous

Free Float
N/A
Market Cap
£454.74 million
Optionable
Not Optionable
Beta
0.92

Key Executives

  • Dr. Roch Doliveux
    Interim CEO & Chairman
  • Mr. Stuart Paynter (Age 49)
    CFO, Company Sec. & Director
    Comp: $755k
  • Mr. Nick Page
    Chief Operations Officer
  • Dr. James Miskin Ph.D.
    Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D.
    Chief Scientific Officer
  • Mr. Matthew Treagus
    Chief Information Officer
  • Sophia Bolhassan
    Head of Investor Relations
  • Ms. Natalie Louise Walter
    Gen. Counsel
  • Dr. Jason Slingsby MBA
    Chief Bus. & Corp. Devel. Officer
  • Ms. Sarah Macleod
    Head of Communications













OXB Stock - Frequently Asked Questions

Should I buy or sell Oxford Biomedica stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OXB shares.
View OXB analyst ratings
or view top-rated stocks.

What is Oxford Biomedica's stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 1,010 to GBX 1,010. On average, they predict the company's stock price to reach GBX 1,010 in the next year. This suggests a possible upside of 115.4% from the stock's current price.
View analysts price targets for OXB
or view top-rated stocks among Wall Street analysts.

How have OXB shares performed in 2023?

Oxford Biomedica's stock was trading at GBX 442.50 on January 1st, 2023. Since then, OXB stock has increased by 6.0% and is now trading at GBX 469.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Oxford Biomedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL).

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford Biomedica?

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Oxford Biomedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 469.

How much money does Oxford Biomedica make?

Oxford Biomedica (LON:OXB) has a market capitalization of £454.74 million and generates £139.99 million in revenue each year. The biopharmaceutical company earns £-39,160,000.00 in net income (profit) each year or GBX (0.42) on an earnings per share basis.

How many employees does Oxford Biomedica have?

The company employs 744 workers across the globe.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page (LON:OXB) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -